Efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients.

Background: Previous reports have demonstrated that S-1 has remarkable effects in the maintenance treatment of advanced non-small-cell lung cancer (NSCLC), and has less toxic and side effects than conventional drugs.

Aim: To investigate the efficacy and safety of S-1 maintenance therapy in patients with advanced NSCLC.

Methods: Ninety-four patients with NSCLC admitted to our hospital from September 2015 to April 2018 were included in the study and divided into the S-1 group (47 cases) and the gemcitabine group (47 cases) by random digital table method.

[Impact of antihypertensive medication timing on degree and stability of blood pressure lowering in patients with essential hypertension].

Objective: To investigate the impact of antihypertensive medication timing on degree and stability of blood pressure (BP) lowering in patients with moderate and severe essential hypertension.

Methods: Ninety patients were randomly assigned to take Valsartan and Felodiping together in the morning (group A), Valsartan in the morning and Felodiping in the evening (group B) or Felodiping in the morning and Valsartan in the evening (group C, n = 30 each). The morning dosage was titrated if the goal blood pressure was not achieved.